Dacogen

Generic name: Decitabine
Drug class: Antimetabolites

Usage of Dacogen

Dacogen is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Dacogen injection is used to treat myelodysplastic syndromes (certain types of blood or bone marrow cancer).

Dacogen may also be used for purposes not listed in this medication guide.

Dacogen side effects

Get emergency medical help if you have signs of an allergic Reaction to Dacogen: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

fever, chills, sore throat;

mouth sores, red or swollen gums, skin sores;

easy bruising, unusual bleeding, purple or red spots under your skin;

pale skin, cold hands and feet; or

cough with mucus, chest pain, feeling short of breath.

Common Dacogen side effects include:

fever or other signs of infection.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Dacogen

To make sure Dacogen is safe for you, tell your doctor if you have ever HAD:

kidney disease; or

liver disease.

You may need to have a negative pregnancy test before starting this treatment.

Decitabine can harm an unborn baby or cause birth defects if the mother or the father is using this medicine.

If you are a woman, do not use Dacogen if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 6 months after your last dose.

If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 3 months after your last dose.

Tell your doctor right away if a pregnancy occurs while either the mother or the father is using Dacogen.

Decitabine may affect fertility (ability to have children) in men. However, it is important to use birth control to prevent pregnancy because decitabine can harm an unborn baby.

You should not breastfeed while using Dacogen and for at least 2 weeks after your last dose.

Relate drugs

How to use Dacogen

Usual Adult Dose for Myelodysplastic Syndrome:

TREATMENT REGIMEN OPTION 1: 15 mg/m2 IV over 3 hours; repeat every 8 hours for 3 days; repeat this cycle every 6 weeks; patients may be premedicated with standard antiemetic therapy If hematologic recovery (ANC 1,000/mcL or greater and platelets 50,000/mcL or greater) from a previous treatment cycle requires more than 6 weeks, then the next cycle should be delayed and dosing temporarily reduced by following this algorithm: -Recovery requiring more than 6, but less than 8 weeks: Delay dosing for up to 2 weeks and temporarily reduce the dose to 11 mg/m2 IV every 8 hours (33 mg/m2/day, 99 mg/m2/cycle) when restarting therapy -Recovery requiring more than 8, but less than 10 weeks: Assess patient for disease progression (by bone marrow aspirates); in the absence of progression, the dose should be delayed up to 2 more weeks and then reduced to 11 mg/m2 IV every 8 hours (33 mg/m2/day, 99 mg/m2/cycle) when restarting therapy, then maintained or increased in subsequent cycles as clinically indicated TREATMENT REGIMEN Option 2: 20 mg/m2 IV over 1 hour; repeat daily for 5 days; repeat this cycle every 4 weeks; patients may be premedicated with standard antiemetic therapy If myelosuppression is present, subsequent treatment cycles should be delayed until there is hematologic recovery (ANC 1,000/mcL or greater and platelets 50,000/mcL or greater) Comments: -With either regimen, it is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial response may take longer than 4 cycles. -Perform complete blood and platelet counts prior to each cycle and as needed to monitor response and toxicity. -Perform liver chemistries and serum creatinine prior to initiation of therapy. Use: For the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups

Warnings

Dacogen affects your immune system. You may get infections more easily. Call your doctor if you have unusual bruising or bleeding, or new signs of infection (fever, chills, cough, sore throat, trouble breathing).

Before receiving a Dacogen injection, tell your doctor if you have liver or kidney disease.

Do not use Dacogen if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment. If a man fathers a child while using decitabine, the baby may have birth defects. Use a condom to prevent pregnancy during your treatment. Continue using condoms for at least 2 months after you stop receiving this medicine. You should not breast-feed while you are receiving this medicine.

What other drugs will affect Dacogen

Other drugs may interact with decitabine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.